http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10806746-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7b48b475857b3558d008f4c78c1981c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-04 |
| filingDate | 2015-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d612d0d9197e51f3382414c5ad96eaeb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79224c4036dafbe4aae33c0078a53021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34fd8540694cc9e67b5eeddf4196229c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_760ba78a9a54bfdb203c34dbc6f7e016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d76f1dca0e5797c668f0ef7ac7060194 |
| publicationDate | 2020-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10806746-B2 |
| titleOfInvention | Di- and tri-cationic glycosylated antitumor ether lipids, L-gucosylated gaels and rhamnose-linked gaels as cytotoxic agents against epithelial cancer cells and cancer stem cells |
| abstract | Glycosylated Antitumor Ether Lipids (GAELs) kill cancer cells by a nonapoptotic pathway which is an attractive strategy to avoid resistance. To further optimize the antitumor effect, we prepared various analogs of di-, and tri-cationic GAEL analogs differing in the nature of the sugar (D-glucose or L-glucose), the anomeric linkage as well as position of the glycerolipid moiety. The di- and tri-cationic GAELs were synthesized and their in vitro anticancer properties were evaluated against drug resistant and aggressively growing cancer cell lines derived from human breast, prostate, pancreatic and ovarian cancers. The most potent dicationic GAEL analogs were also studied against cancer stem cells obtained from breast BT 474, prostate DU145 and ovarian A2780cp cell lines. Our results indicate that the number of positive charges, the position of the amino substituents and the nature of the sugar have significant effects on the anticancer activities of these compounds. The most active analog kill 50% of the cells at concentration range of 0.5-5 μM and 90% of the cells at the concentration of 1-10 μM depending on type of cancer cells. |
| priorityDate | 2014-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 470.